Nanrilkefusp Alfa (SOT101), an IL-15 Receptor βγ Superagonist, as a Single Agent or With Anti-PD-1 in Patients With Advanced Cancers

Authors

Stephane Champiat
Elena Garralda
Vladimir Galvao
Philippe A Cassier
Carlos Gomez-Roca
Iphigenie Korakis
Peter Grell
Aung Naing
Patricia LoRusso
Romana Mikyskova
Nada Podzimkova
Milan Reinis
Kaissa Ouali
Andreu Schoenenberger
Joachim Kiemle-Kallee
Sascha Tillmanns
Richard Sachse
Ulrich Moebius
Radek Spisek
David Bechard
Lenka Palova Jelinkova
Irena Adkins
Aurelien Marabelle

Publication Date

2-18-2025

Journal

Cell Reports Medicine

DOI

10.1016/j.xcrm.2025.101967

PMID

39933529

PMCID

PMC11866505

PubMedCentral® Posted Date

2-10-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor βγ superagonist that stimulates natural killer (NK) and CD8

Keywords

Humans, Animals, Neoplasms, Programmed Cell Death 1 Receptor, Macaca fascicularis, Female, Male, Middle Aged, Aged, Receptors, Interleukin-15, Killer Cells, Natural, CD8-Positive T-Lymphocytes, Adult, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors

Published Open-Access

yes

Recommended Citation

Champiat, Stephane; Garralda, Elena; Galvao, Vladimir; et al., "Nanrilkefusp Alfa (SOT101), an IL-15 Receptor βγ Superagonist, as a Single Agent or With Anti-PD-1 in Patients With Advanced Cancers" (2025). Faculty, Staff and Student Publications. 4874.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4874